Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome

Autoimmunity Reviews

Volumn 14, Issue 7, 2015, Pages 641-649

  Papageorgiou, Aristea ^a   Voulgarelis, Michael ^a   Tzioufas, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Lymphoma; Outcome; Predictors; Prognosis; Sj gren's syndrome

Indexed keywords

CD135 ANTIGEN; VITAMIN D;

B LYMPHOCYTE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; GLOMERULONEPHRITIS; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERACTIVITY; HYPERGAMMAGLOBULINEMIA; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; META ANALYSIS (TOPIC); NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGNOSTIC ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALIVARY GLAND; SEROLOGY; SJOEGREN SYNDROME; COMPLICATION; IMMUNOLOGY; LYMPHOMA;

HUMANS; IMMUNOPHENOTYPING; LYMPHOMA; PROGNOSIS; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84928927925     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.03.004     Document Type: Review

References (92)

1. Mavragani C.P., Moutsopoulos H.M. Sjogren syndrome. CMAJ 2014, 186:E579-E586.
2. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
3. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002, 46:741-747.
4. Theander E., Manthorpe R., Jacobsson L.T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004, 50:1262-1269.
5. Alamanos Y., Tsifetaki N., Voulgari P.V., Venetsanopoulou A.I., Siozos C., Drosos A.A. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 2006, 45:187-191.
6. Pertovaara M., Pukkala E., Laippala P., Miettinen A., Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001, 60:467-472.
7. Brito-Zeron P., Ramos-Casals M., Bove A., Sentis J., Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007, 46:1359-1362.
8. Ramos-Casals M., Brito-Zeron P., Yague J., Akasbi M., Bautista R., Ruano M., et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005, 44:89-94.
9. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in Sicca syndrome. Ann Intern Med 1978, 89:888-892.
10. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
11. Anaya J.M., McGuff H.S., Banks P.M., Talal N. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 1996, 25:337-346.
12. Valesini G., Priori R., Bavoillot D., Osborn J., Danieli M.G., Del Papa N., et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997, 24:2376-2380.
13. Solans-Laque R., Lopez-Hernandez A., Bosch-Gil J.A., Palacios A., Campillo M., Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 2011, 41:415-423.
14. Anderson L.G., Talal N. The spectrum of benign to malignant lymphoproliferation in Sjogren's syndrome. Clin Exp Immunol 1972, 10:199-221.
15. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's syndrome. Arthritis Rheum 1999, 42:1765-1772.
16. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
17. Tarella C., Gueli A., Ruella M., Cignetti A. Lymphocyte transformation and autoimmune disorders. Autoimmun Rev 2013, 12:802-813.
18. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88:284-293.
19. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
20. Anderson L.A., Gadalla S., Morton L.M., Landgren O., Pfeiffer R., Warren J.L., et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009, 125:398-405.
21. Mariette X. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 1999, 33:93-99.
22. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012, 91:1-9.
23. Papageorgiou A., Ziogas D.C., Mavragani C.P., Zintzaras E., Tzioufas A.G., Moutsopoulos H.M., et al. Predicting the outcome of Sjogren's syndrome-associated non-Hodgkin's lymphoma patients. PLoS One 2015, 10:e0116189.
24. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J.M., Soussi T., et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997, 90:766-775.
25. Ambrosetti A., Zanotti R., Pattaro C., Lenzi L., Chilosi M., Caramaschi P., et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjogren syndrome or hepatitis C virus infection. Br J Haematol 2004, 126:43-49.
26. Pollard R.P., Pijpe J., Bootsma H., Spijkervet F.K., Kluin P.M., Roodenburg J.L., et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol 2011, 38:2198-2208.
27. Cohen C., Mekinian A., Uzunhan Y., Fauchais A.L., Dhote R., Pop G., et al. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjogren's syndrome. Autoimmun Rev 2013, 12:1109-1114.
28. Baldini C., Mosca M., Della Rossa A., Pepe P., Notarstefano C., Ferro F., et al. Overlap of ACA-positive systemic sclerosis and Sjogren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol 2013, 31:272-280.
29. Sutcliffe N., Inanc M., Speight P., Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 1998, 28:80-87.
30. Zhang W., Feng S., Yan S., Zhao Y., Li M., Sun J., et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010, 49:571-577.
31. Baldini C., Pepe P., Luciano N., Ferro F., Talarico R., Grossi S., et al. A clinical prediction rule for lymphoma development in primary Sjogren's syndrome. J Rheumatol 2012, 39:804-808.
32. Goules A.V., Tatouli I.P., Moutsopoulos H.M., Tzioufas A.G. Clinically significant renal involvement in primary Sjogren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013, 65:2945-2953.
33. Risselada A.P., Kruize A.A., Bijlsma J.W. Clinical features distinguishing lymphoma development in primary Sjogren's syndrome-a retrospective cohort study. Semin Arthritis Rheum 2013, 43:171-177.
34. Nishishinya M.B., Pereda C.A., Munoz-Fernandez S., Pego-Reigosa J.M., Rua-Figueroa I., Andreu J.L., et al. Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015, 35:17-26.
35. Kirtava Z., Blomberg J., Bredberg A., Henriksson G., Jacobsson L., Manthorpe R. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjogren's syndrome. Clin Exp Rheumatol 1995, 13:609-616.
36. Henriksson G., Manthorpe R., Bredberg A. Antibodies to CD4 in primary Sjogren's syndrome. Rheumatology (Oxford) 2000, 39:142-147.
37. Mandl T., Bredberg A., Jacobsson L.T., Manthorpe R., Henriksson G. CD4+ T-lymphocytopenia-a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren's syndrome. J Rheumatol 2004, 31:726-728.
38. Triantafyllopoulou A., Tapinos N., Moutsopoulos H.M. Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2004, 50:2897-2902.
39. Cesana C., Barbarano L., Miqueleiz S., Lucchesini C., Ricci F., Varettoni M., et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 2005, 5:261-264.
40. Moutsopoulos H.M., Tzioufas A.G., Bai M.K., Papadopoulos N.M., Papadimitriou C.S. Association of serum IgM kappa monoclonicity in patients with Sjogren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands. Ann Rheum Dis 1990, 49:929-931.
41. Brito-Zeron P., Retamozo S., Gandia M., Akasbi M., Perez-De-Lis M., Diaz-Lagares C., et al. Monoclonal gammopathy related to Sjogren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 2012, 39:43-48.
42. Tzioufas A.G., Manoussakis M.N., Costello R., Silis M., Papadopoulos N.M., Moutsopoulos H.M. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjogren's syndrome. Arthritis Rheum 1986, 29:1098-1104.
43. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996, 39:767-772.
44. De Vita S., Quartuccio L., Salvin S., Corazza L., Zabotti A., Fabris M. Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology (Oxford) 2012, 51:627-633.
45. Gottenberg J.E., Seror R., Miceli-Richard C., Benessiano J., Devauchelle-Pensec V., Dieude P., et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013, 8:e59868.
46. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
47. Agmon-Levin N., Kivity S., Tzioufas A.G., Lopez Hoyos M., Rozman B., Efes I., et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. J Autoimmun 2012, 39:234-239.
48. Tincani A., Andreoli L., Cavazzana I., Doria A., Favero M., Fenini M.G., et al. Novel aspects of Sjogren's syndrome in 2012. BMC Med 2013, 11:93.
49. Terrier B., Chaara W., Dufat L., Geri G., Rosenzwajg M., Musset L., et al. Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmun Rev 2014, 13:319-326.
50. De Vita S., De Re V., Gasparotto D., Ballare M., Pivetta B., Ferraccioli G., et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000, 43:94-102.
51. De Vita S., De Marchi G., Sacco S., Gremese E., Fabris M., Ferraccioli G. Preliminary classification of nonmalignant B cell proliferation in Sjogren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001, 27:757-766.
52. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011, 70:1363-1368.
53. Risselada A.P., Looije M.F., Kruize A.A., Bijlsma J.W., van Roon J.A. The role of ectopic germinal centers in the immunopathology of primary Sjogren's syndrome: a systematic review. Semin Arthritis Rheum 2013, 42:368-376.
54. Bombardieri M., Barone F., Humby F., Kelly S., McGurk M., Morgan P., et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 2007, 179:4929-4938.
55. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
56. Mebius R.E. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003, 3:292-303.
57. Barone F., Bombardieri M., Rosado M.M., Morgan P.R., Challacombe S.J., De Vita S., et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008, 180:5130-5140.
58. Ludewig B., Junt T., Hengartner H., Zinkernagel R.M. Dendritic cells in autoimmune diseases. Curr Opin Immunol 2001, 13:657-662.
59. Dinarello C.A. Interleukin-18. Methods 1999, 19:121-132.
60. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998, 16:495-521.
61. Manoussakis M.N., Boiu S., Korkolopoulou P., Kapsogeorgou E.K., Kavantzas N., Ziakas P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007, 56:3977-3988.
62. Risselada A.P., Kruize A.A., Goldschmeding R., Lafeber F.P., Bijlsma J.W., van Roon J.A. The prognostic value of routinely performed minor salivary gland assessments in primary Sjogren's syndrome. Ann Rheum Dis 2014, 73:1537-1540.
63. Tapinos N.I., Polihronis M., Moutsopoulos H.M. Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum 1999, 42:1466-1472.
64. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science 1994, 266:1821-1828.
65. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 Mutations in human cancers. Science 1991, 253:49-53.
66. Tangye S.G., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
67. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
68. Mackay F., Groom J.R., Tangye S.G. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2007, 19:406-413.
69. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005, 25:189-201.
70. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
71. Ittah M., Miceli-Richard C., Eric Gottenberg J., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006, 8:R51.
72. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171.
73. Novak A.J., Grote D.M., Stenson M., Ziesmer S.C., Witzig T.E., Habermann T.M., et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004, 104:2247-2253.
74. Bossen C., Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006, 18:263-275.
75. He B., Chadburn A., Jou E., Schattner E.J., Knowles D.M., Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004, 172:3268-3279.
76. Quartuccio L., Salvin S., Fabris M., Maset M., Pontarini E., Isola M., et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013, 52:276-281.
77. Nezos A., Papageorgiou A., Fragoulis G., Ioakeimidis D., Koutsilieris M., Tzioufas A.G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun 2014, 51:89-98.
78. Reksten T.R., Johnsen S.J., Jonsson M.V., Omdal R., Brun J.G., Theander E., et al. Genetic associations to germinal centre formation in primary Sjogren's syndrome. Ann Rheum Dis 2014, 73:1253-1258.
79. Lisovsky M., Braun S.E., Ge Y., Takahira H., Lu L., Savchenko V.G., et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996, 10:1012-1018.
80. Antonysamy M.A., Thomson A.W. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 2000, 12:87-100.
81. Tobon G.J., Renaudineau Y., Hillion S., Cornec D., Devauchelle-Pensec V., Youinou P., et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2010, 62:3447-3456.
82. Tobon G.J., Saraux A., Gottenberg J.E., Quartuccio L., Fabris M., Seror R., et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2013, 65:3218-3227.
83. Ma A., Malynn B.A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012, 12:774-785.
84. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
85. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
86. Novak U., Rinaldi A., Kwee I., Nandula S.V., Rancoita P.M., Compagno M., et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113:4918-4921.
87. Nocturne G., Boudaoud S., Miceli-Richard C., Viengchareun S., Lazure T., Nititham J., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013, 122:4068-4076.
88. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
89. Saadoun D., Terrier B., Bannock J., Vazquez T., Massad C., Kang I., et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013, 65:1085-1096.
90. Visentini M., Conti V., Cristofoletti C., Lazzeri C., Marrapodi R., Russo G., et al. Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun Rev 2013, 12:430-435.
91. Brito-Zeron P., Kostov B., Solans R., Fraile G., Suarez-Cuervo C., Casanovas A., et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients 2014.
92. Sarris A.H., Papadimitrakopoulou V., Dimopoulos M.A., Smith T., Pugh W., Ha C.S., et al. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma 1997, 26:49-56.